UCBJY - UCB SA

Other OTC - Other OTC Delayed Price. Currency in USD
35.84
0.00 (0.00%)
At close: 3:39PM EDT
Stock chart is not supported by your current browser
Previous Close35.84
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume101
Market Cap13.606B
Beta0.39
PE Ratio (TTM)17.79
EPS (TTM)2.01
Earnings DateN/A
Forward Dividend & Yield0.63 (1.75%)
Ex-Dividend Date2017-04-28
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire16 days ago

    UCB Presents New Findings Advancing Patient Care for Chronic Inflammatory Diseases and Osteoporosis at 2017 ACR/ARHP Annual Meeting

    BRUSSELS , Nov. 6, 2017 /PRNewswire/ -- Key data focus on inflammatory and osteoporosis in patient populations with unmet needs including women of childbearing age and others: The results from the first-of-its-kind ...

  • PR Newswire16 days ago

    UCB's VIMPAT® (lacosamide) now approved by FDA to treat partial-onset seizures in pediatric epilepsy patients

    ATLANTA and BRUSSELS , Nov. 6, 2017 /PRNewswire/ --  VIMPAT® (lacosamide) CV oral formulations are approved as a monotherapy or adjunctive therapy in patients four years of age and older with partial-onset ...

  • Regulus Therapeutics (RGLS) Looks Good: Stock Adds 5.6% in Session
    Zacks2 months ago

    Regulus Therapeutics (RGLS) Looks Good: Stock Adds 5.6% in Session

    Regulus Therapeutics Inc. (RGLS) was a big mover last session, as the company saw its shares rise nearly 6% on the day amid huge volumes

  • PR Newswire2 months ago

    New indication for BRIVIACT® (brivaracetam): UCB's newest antiepileptic drug approved by FDA as monotherapy treatment of partial-onset seizures in adults

    -- New indication comes just 18 months after launch of BRIVIACT® in the U.S. This is a new indication for BRIVIACT, which is already approved in the U.S. as adjunctive treatment for POS in patients in this age group.

  • PR Newswire2 months ago

    EVENITY™ (romosozumab) ARCH Study Results Published In The New England Journal Of Medicine

    THOUSAND OAKS, Calif. and BRUSSELS, Sept. 11, 2017 /PRNewswire/ -- Amgen (AMGN) and UCB (Euronext Brussels: UCB) today announced detailed results from the Phase 3 ARCH study showing that 12 months of EVENITY™* (romosozumab) followed by alendronate was superior in reducing new vertebral, clinical, non-vertebral and hip fracture risk in postmenopausal women with osteoporosis at high risk for fracture, compared to alendronate alone. Overall adverse events and serious adverse events were generally similar between the treatment groups with the exception of the previously reported imbalance in positively adjudicated cardiovascular serious adverse events.

  • UCB SA :UCBJY-US: Earnings Analysis: For the six months ended June 30, 2017 : August 1, 2017
    Capital Cube4 months ago

    UCB SA :UCBJY-US: Earnings Analysis: For the six months ended June 30, 2017 : August 1, 2017

    Categories: Yahoo FinanceGet free summary analysis UCB SA reports financial results for the half-year ended June 30, 2017. We analyze the earnings along side the following peers of UCB SA – Amgen Inc., Biogen Inc. and Novartis AG Sponsored ADR (AMGN-US, BIIB-US and NVS-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD ... Read more (Read more...)

  • PR Newswire4 months ago

    Amgen And UCB Provide Update On Regulatory Status Of EVENITY™ (romosozumab) In The US

    THOUSAND OAKS, Calif. and BRUSSELS, July 16, 2017 /PRNewswire/ -- Amgen (AMGN) and UCB (Euronext Brussels: UCB) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the Biologics License Application (BLA) for EVENITY™* (romosozumab) as a treatment for postmenopausal women with osteoporosis. The original submission included data from the pivotal Phase 3 placebo-controlled FRAME study of postmenopausal women with osteoporosis. The resubmission will also include the efficacy and safety data from the BRIDGE study, the Phase 3 trial evaluating EVENITY in men with osteoporosis, which has also been requested.

  • PR Newswire5 months ago

    Results from CRIB study on CIMZIA® (certolizumab pegol) demonstrate minimal to no placental transfer of drug from mother to infant during third trimester of pregnancy

    BRUSSELS, June 13, 2017 /PRNewswire/ -- UCB today presented results from CRIB, a pharmacokinetic study designed to assess if CIMZIA® (certolizumab pegol) is transferred across the placenta from pregnant women to their infants. The study used a sensitive immunoassay designed specifically to measure CIMZIA and found no measurable levels in 13 out of 14 infant blood samples at birth, and in all infant samples at weeks four and eight after birth.

  • TheStreet.com6 months ago

    UCB Stock Plunges After Trials Reveal Safety Risk in Amgen JV

    UCB stock plummeted Monday after clinical trials shone a light over a possible safety risk related to the Osteoporosis treatment that it has been developing alongside Amgen

  • PR Newswire6 months ago

    Amgen And UCB Announce Top-Line Phase 3 Data From Active-Comparator Study Of EVENITY™ (Romosozumab) In Postmenopausal Women With Osteoporosis

    THOUSAND OAKS, Calif. and BRUSSELS, May 21, 2017 /PRNewswire/ -- Amgen (AMGN) and UCB (Euronext Brussels: UCB) today announced that the EVENITY™* (romosozumab) ARCH study met both primary endpoints and the key secondary endpoint. At the primary analysis, treatment with EVENITY for 12 months followed by alendronate significantly reduced the incidence of new vertebral fractures through 24 months, clinical fractures (primary endpoints) and non-vertebral fractures (key secondary endpoint) in postmenopausal women with osteoporosis at high risk for fracture, compared to alendronate alone.

  • UCB SA : UCBJY-US: Dividend Analysis : May 02nd, 2017 (record date) : By the numbers : April 28, 2017
    Capital Cube7 months ago

    UCB SA : UCBJY-US: Dividend Analysis : May 02nd, 2017 (record date) : By the numbers : April 28, 2017

    Categories: Yahoo FinanceGet free summary analysis Our analysis is based on comparing UCB SA with the following peers – Amgen Inc., Shire PLC Sponsored ADR, Pfizer Inc., Biogen Inc., Novartis AG Sponsored ADR and Catalyst Pharmaceuticals, Inc. (AMGN-US, SHPG-US, PFE-US, BIIB-US, NVS-US and CPRX-US). UCB SA’s dividend yield is 1.03 percent and its dividend payout is 24.00 ... Read more (Read more...)

  • PR Newswire7 months ago

    UCB showcases latest epilepsy research at 2017 Annual Meeting of the American Academy of Neurology

    Data being presented include posters further describing the efficacy and tolerability profile of VIMPAT® (lacosamide) CV and BRIVIACT® (brivaracetam) CV. Posters will be presented describing the efficacy and tolerability of lacosamide monotherapy in elderly newly diagnosed epilepsy patients and in newly diagnosed epilepsy patients with psychiatric comorbidities. Pooled results from long-term follow-up studies of adjunctive brivaracetam in patients with secondarily generalized tonic-clonic seizures and a poster comparing the healthcare utilization and direct medical costs in newly diagnosed epilepsy patients compared to a non-epilepsy population will also be presented.

  • PR Newswire7 months ago

    Labor Commissioner Mark Butler Joins Atlanta Businesses at the EFWorks Launch Forum

    ATLANTA, April 11, 2017 /PRNewswire/ -- The Epilepsy Foundation of Georgia (EFGA), with sponsorship from UCB, Inc., a biopharmaceutical company, had the pleasure of hosting Georgia Labor Commissioner Mark Butler and Atlanta-area business at the EFWorks Employer Forum. Attendees included companies large and small.

  • PR Newswire7 months ago

    1CellBiO Inc announces Collaboration Agreement with UCB

    CAMBRIDGE, Mass., April 11, 2017 /PRNewswire/ -- 1CellBiO Inc announced today a research collaboration with UCB to validate and deploy the inDrop ™ high throughput single cell RNA sequencing platform in ...

  • PR Newswire8 months ago

    Amgen And UCB Report New Data At ENDO 2017 Examining The Option Of A Second Course Of Treatment With EVENITY™ (romosozumab)

    In the study, postmenopausal women with low bone mass (lumbar spine, total hip or femoral neck T score between -2.0 and -3.5) were initially randomized to various doses of EVENITY or placebo for 24 months and then re-randomized to receive denosumab (Prolia®) or placebo for the next 12 months (24 to 36 months), as previously reported. For months 36 to 48, all of these patients were then treated with EVENITY (210 mg) for 12 months.

  • PR Newswire8 months ago

    UCB Launches Wellness 4U, an Innovative and Comprehensive Health and Wellness Program for Patients with Immunologic Diseases

    ATLANTA, March 15, 2017 /PRNewswire/ -- UCB, a global biopharmaceutical company focusing on immunology, neurology and bone treatments and research, has launched Wellness 4U™, an insights-driven health and wellness program that is dedicated to promoting healthier lifestyles. Wellness 4U is a multi-channel health and wellness program that utilizes several initiatives aimed to elevate patient outcomes beyond therapeutic support for people living with immunologic disorders and their healthcare professionals. Key Wellness 4U programs include a Wellness 4U Activity Tracker, a health outcomes research collaboration with the IBD Support Foundation, a national wellness education panel speaker event series addressing the entire care team and a nurse practitioner/physician's assistant educational initiative.

  • PR Newswire9 months ago

    First CIMZIA® (certolizumab pegol) Study of Its Kind Showed Minimal to No Transfer of Drug from Mother's Plasma to Breast Milk

    BRUSSELS, March 6, 2017 /PRNewswire/ -- Today UCB announced results from the CRADLE study, the first lactation study designed to evaluate CIMZIA® (certolizumab pegol) concentrations in human mature breast milk and to estimate the average daily infant dose of the drug in maternal breast milk, in accordance with guidance from the US Food & Drug Administration. The study used a bioanalytical assay specifically designed for CIMZIA, offering significantly improved sensitivity and specificity over previously used plasma assays. The reported results indicate minimal to no transfer of CIMZIA into breast milk, a minimal average daily infant dose, and a relative infant dose, considered to be in the acceptable range for breastfeeding.

  • UCB SA :UCBJY-US: Earnings Analysis: 2016 By the Numbers : February 28, 2017
    Capital Cube9 months ago

    UCB SA :UCBJY-US: Earnings Analysis: 2016 By the Numbers : February 28, 2017

    Categories: Yahoo Finance Get free summary analysis UCB SA reports financial results for the year ended December 31, 2016. We analyze the earnings along side the following peers of UCB SA – Shire PLC Sponsored ADR, Amgen Inc., Pfizer Inc., Biogen Inc. and Novartis AG Sponsored ADR (SHPG-US, AMGN-US, PFE-US, BIIB-US and NVS-US) that have also reported for ... Read more (Read more...)

  • UCB SA :UCBJY-US: Earnings Analysis: For the six months ended December 31, 2016 : February 28, 2017
    Capital Cube9 months ago

    UCB SA :UCBJY-US: Earnings Analysis: For the six months ended December 31, 2016 : February 28, 2017

    Categories: Yahoo Finance Get free summary analysis UCB SA reports financial results for the half-year ended December 31, 2016. We analyze the earnings along side the following peers of UCB SA – Shire PLC Sponsored ADR, Amgen Inc., Pfizer Inc., Biogen Inc. and Novartis AG Sponsored ADR (SHPG-US, AMGN-US, PFE-US, BIIB-US and NVS-US) that have also reported for ... Read more (Read more...)

  • PR Newswire11 months ago

    Amgen And UCB Announce Submission Of Application For Investigational Osteoporosis Medication Romosozumab In Japan

    THOUSAND OAKS, Calif. and BRUSSELS, Dec. 19, 2016 /PRNewswire/ -- Amgen (AMGN) and UCB (Euronext Brussels: UCB) today announced that an application seeking marketing approval of romosozumab for the treatment of osteoporosis for those at high risk of fracture has been submitted for review to the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. Amgen and UCB are co-developing romosozumab worldwide, with development in Japan being led by Amgen Astellas BioPharma (AABP) K.K., a joint venture between Amgen and Astellas Pharma Inc., a pharmaceutical company headquartered in Tokyo.